A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Clinical trial NCT05732805 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05732805
Sponsor: Biocad
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Melanoma Melanoma (Skin)Melanoma Stage III Melanoma Stage IV Melanoma Unresectable Melanoma Metastatic Melanoma Advanced

Start date: 2022-08-02
Primary completion: 2024-06-20
Enrollment: 270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.